EE390 Healthcare Resource Utilization (HCRU) and Costs in Patients with Metastatic Urothelial Cancer (MUC) Who Received First-Line (1L) Treatment: Results from Impact UC II

M.A. Bilen, B. Diessner,J. White, M. Kirker, F. Liu,A. Nguyen, N. Gharibian, G. Devgan, H. Katzenstein,A. Bhanegaonkar

Value in Health（2023）

引用 0|浏览1

暂无评分

摘要

Recent drug approvals have changed the treatment landscape for mUC; however, real-world data on HCRU and costs are limited. Here, we describe HCRU and costs by 1L treatment in mUC.

查看译文

关键词

metastatic urothelial cancer,costs,first-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要